Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in High-Risk Smoldering Multiple Myeloma
NCT03792763Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in smoldering multiple myeloma (SMM) and multiple myeloma (MM) comparing Denosumab with Placebo (2 arms). Primary endpoint: Time to progression at 78 months. Started Sep 2019; status: completed.
02
Drugs
denosumab
03
Conditions
smoldering multiple myeloma (SMM)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03792763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792763.